Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 19/20 | 0.48 |
| ▸ | GUCY1A2 | P33402 | 19/20 | 0.48 |
| ▸ | GUCY1A1 | Q02108 | 19/20 | 0.48 |
| ▸ | GUCY1B1 | Q02153 | 19/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15665236 | 0.89 | GUCY1B2 (0.46) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15670439 | 0.87 | GUCY1B2 (0.44) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15664222 | 0.86 | GUCY1B2 (0.52) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15663508 | 0.86 | GUCY1B2 (0.52) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL18573934 | 0.85 | GUCY1B2 (0.50) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15663482 | 0.85 | PTGER1 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15663596 | 0.85 | GUCY1B2 (0.50) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15686121 | 0.84 | GUCY1B2 (0.49) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL17123169 | 0.84 | GUCY1B2 (0.54) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15671374 | 0.84 | GUCY1B2 (0.49) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914596-B1 | HYDROXY SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE CARBOXAMIDES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| US-8946215-B2 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946215-B2 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946215-B2 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8778964-B2 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-07-15 | — | — | US | disclosed |
| US-8778964-B2 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-07-15 | — | — | US | disclosed |
| US-8778964-B2 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-07-15 | — | — | US | disclosed |
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128424-A1 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128424-A1 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128424-A1 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | AADAC, TNNI3, PAH | GUCY1B2 793/4885GUCY1A2 719/4885GUCY1A1 1052/4885 |
| US-20140128424-A1 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | TNNI3, AADAC, TNNT2 | GUCY1B2 866/4885GUCY1A2 684/4885GUCY1A1 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.